A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

Project: Research project

Project Details

StatusFinished
Effective start/end date9/1/13 → 6/30/18

Funding

  • Novartis Pharmaceuticals Corporation: $79,802.00